Literature DB >> 28763625

MicroRNA-1-3p inhibits the proliferation and migration of oral squamous cell carcinoma cells by targeting DKK1.

Zhenshi Wang1,2, Jiaolong Wang1,2, Zhihua Chen3, Kun Wang1,2, Lianshui Shi1,2.   

Abstract

We investigated the functional role and mechanism of miR-1-3p and DKK1 in oral squamous cell carcinoma (OSCC) cells. The level of miR-1-3p and DKK1 expression were detected in OSCC tissues and cells using reverse-transcription - quantitative PCR and Western blot. A dual luciferase reporter gene assay was applied to confirm the targeting relationship between miR-1-3p and DKK1. Functional assays, including MTT, Transwell, colony formation, and flow cytometry analysis were conducted to verify their effect on cell progressions. MTT, colony formation, and Transwell assays indicated that the proliferation, migration, and invasion of SCC-4 cells was impaired with high miR-1-3p expression but promoted with high DKK1 expression. The results from cell cycle analysis and annexin-V-PI assays for apoptosis suggested that miR-1-3p suppressed the transit of SCC-4 cells from G0/G1 to S and induced apoptosis. In summary, miR-1-3p suppressed the progression of OSCC by inhibiting DKK1 expression.

Entities:  

Keywords:  CECO; DKK1; OSCC; SCC-4 cells; cellules SCC-4; miR-1-3p

Mesh:

Substances:

Year:  2017        PMID: 28763625     DOI: 10.1139/bcb-2017-0015

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  16 in total

1.  Propofol regulates miR-1-3p/IGF1 axis to inhibit the proliferation and accelerates apoptosis of colorectal cancer cells.

Authors:  Ling-Ling Ye; Zhong-Gui Cheng; Xiao-E Cheng; Yuan-Lu Huang
Journal:  Toxicol Res (Camb)       Date:  2021-06-14       Impact factor: 2.680

2.  [microRNA-1 gene delivery mediated by exosomes suppresses CAL-27 cell proliferation].

Authors:  Bao-Qin Wu; Chun-Hui Li; Meng-Lian Zhang; Min-Hai Nie
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2021-04-01

3.  Involvement of RUVBL1 in WNT/β-Catenin Signaling in Oral Squamous Cell Carcinoma.

Authors:  Yongfa Zeng; Ying Kong; Lan Liao; Hongshui Zhu
Journal:  Dis Markers       Date:  2022-04-22       Impact factor: 3.464

4.  miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9.

Authors:  Hao Zhang; Zhenya Zhang; Lili Gao; Zhengdong Qiao; Minghua Yu; Bo Yu; Tao Yang
Journal:  Onco Targets Ther       Date:  2019-03-22       Impact factor: 4.147

5.  Silencing of MALAT1 inhibits migration and invasion by sponging miR‑1‑3p in prostate cancer cells.

Authors:  Xiaofan Dai; Zuowen Liang; Lingyun Liu; Kaimin Guo; Shengqi Xu; Hongliang Wang
Journal:  Mol Med Rep       Date:  2019-08-22       Impact factor: 2.952

Review 6.  The Clinical Diagnostic and Prognostic Value of Dickkopf-1 in Cancer.

Authors:  Jie Li; Yan Gao; Wentao Yue
Journal:  Cancer Manag Res       Date:  2020-06-08       Impact factor: 3.989

Review 7.  Insight toward the MicroRNA Profiling of Laryngeal Cancers: Biological Role and Clinical Impact.

Authors:  Takashi Takeuchi; Hiromichi Kawasaki; Amalia Luce; Alessia Maria Cossu; Gabriella Misso; Marianna Scrima; Marco Bocchetti; Filippo Ricciardiello; Michele Caraglia; Silvia Zappavigna
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

Review 8.  MicroRNAs as Theranostics Targets in Oral Carcinoma Stem Cells.

Authors:  Pei-Ling Hsieh; Yi-Wen Liao; Martin Pichler; Cheng-Chia Yu
Journal:  Cancers (Basel)       Date:  2020-02-03       Impact factor: 6.639

9.  The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1.

Authors:  Sen-Mao Li; Huan-Lei Wu; Xiao Yu; Kun Tang; Shao-Gang Wang; Zhang-Qun Ye; Jia Hu
Journal:  J Exp Clin Cancer Res       Date:  2018-09-05

10.  Clinical significance of miRNA‑1 and its potential target gene network in lung squamous cell carcinoma.

Authors:  Xiaojiao Li; Meijiao Qin; Jiacheng Huang; Jie Ma; Xiaohua Hu
Journal:  Mol Med Rep       Date:  2019-04-19       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.